Evolus, Inc.
$5.08
▼
-6.5%
2026-04-21 06:39:01
www.evolus.com
NGM: EOLS
Explore Evolus, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$330.5 M
Current Price
$5.08
52W High / Low
$12.28 / $3.86
Stock P/E
—
Book Value
$-0.35
Dividend Yield
—
ROCE
-24.97%
ROE
587.36%
Face Value
—
EPS
$-0.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
334
Beta
1
Debt / Equity
-6.71
Current Ratio
1.9
Quick Ratio
1.54
Forward P/E
17.79
Price / Sales
0.93
Enterprise Value
$378.98 M
EV / EBITDA
-12.59
EV / Revenue
1.27
Rating
None
Target Price
$14.67
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Collegium Pharmaceutical, Inc. | $34.31 | 17.33 | $1.09 B | — | 14.67% | 23.7% | $50.79 / $25.86 | $9.51 |
| 2. | Amneal Pharmaceuticals, Inc. | $13.26 | 58.7 | $4.23 B | — | 14.23% | -80.04% | $15.42 / $7.01 | $-0.23 |
| 3. | Amphastar Pharmaceuticals, Inc. | $22.92 | 10.43 | $1.02 B | — | 9.54% | 12.9% | $31.26 / $17.03 | $17.28 |
| 4. | Aurora Cannabis Inc. | $3.72 | — | $285.82 M | — | 1.34% | -15.51% | $9.33 / $4.29 | $6.8 |
| 5. | Liquidia Corporation | $37.66 | — | $3.32 B | — | -26.74% | -1.11% | $46.67 / $11.85 | $0.51 |
| 6. | Caring Brands, Inc. | $1.25 | — | — | — | -157.44% | -2.17% | $6 / $0.06 | $0.14 |
| 7. | Kamada Ltd. | $8.32 | 23.76 | $479.95 M | 3% | 7.92% | 7.64% | $9.35 / $6.35 | $4.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 90.3 M | 68.97 M | 69.39 M | 68.52 M | 78.95 M |
| Operating Profit | -0.29 M | -10.16 M | -14.12 M | -13.02 M | -0.75 M |
| Net Profit | 0.13 M | -15.74 M | -17.14 M | -18.89 M | -6.79 M |
| EPS in Rs | 0 | -0.24 | -0.26 | -0.29 | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 297.18 M | 266.27 M | 202.09 M | 148.62 M |
| Operating Profit | -37.6 M | -27.23 M | -44.98 M | -59.58 M |
| Net Profit | -51.64 M | -50.42 M | -61.69 M | -74.41 M |
| EPS in Rs | -0.79 | -0.77 | -0.95 | -1.14 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 225.87 M | 232.57 M | 189 M | 177.98 M |
| Total Liabilities | 248.97 M | 227.05 M | 209.69 M | 159.48 M |
| Equity | -23.11 M | 5.52 M | -20.69 M | 18.5 M |
| Current Assets | 142.92 M | 151.34 M | 112.42 M | 100.8 M |
| Current Liabilities | 75.31 M | 62.96 M | 48.29 M | 46.51 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -42.27 M | -18 M | -34.01 M | -84.91 M |
| Investing CF | -8.45 M | -4.82 M | -1.63 M | -2.94 M |
| Financing CF | 17.34 M | 47.41 M | 44.64 M | -4.15 M |
| Free CF | -50.72 M | -22.82 M | -35.63 M | -87.85 M |
| Capex | -8.45 M | -4.82 M | -1.63 M | -2.94 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 31.76% | 35.98% | — | — |
| Earnings Growth % | 18.26% | 17.1% | — | — |
| Profit Margin % | -18.94% | -30.52% | -50.07% | — |
| Operating Margin % | -10.23% | -22.26% | -40.09% | — |
| Gross Margin % | 68.46% | 68.08% | 60.41% | — |
| EBITDA Margin % | -9.39% | -20.69% | -40.86% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.